Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Targeted Therapies in Asthma: Update Bulletin #2 [April 2018]

Product Code:
596200982
Publication Date:
April 2018
Format:
PDF
Price:
£910

Gain new key opinion leader (KOL) insights on the latest events happening in targeted therapies for asthma. Topics covered include; expert opinions on the potential of GSK’s anti-IL-33 mAb GSK3772847; KOL views on dupilumab (Dupixent; Sanofi/Regeneron); and views on the results of the Phase IV OSMO trial carried out in subjects with severe eosinophilic asthma not optimally controlled with Xolair (omalizumab; Novartis/Roche) treatment who were switched from omalizumab to Nucala (mepolizumab; GSK)

Business Questions:

• How do KOLs perceive GSK3772847’s mechanism of action?
• What are KOLs’ views on the design of GSK3772847’s Phase II study?
• What concerns do KOLs raise about using anti-IL-33 therapies in combination?
• Do KOLs anticipate dupilumab use will be limited to those patients with higher eosinophils?
• What advantages and disadvantages does dupilumab have over other biological therapies?
• What safety concerns do KOLs raise regarding the use of dupilumab?
• What impact do experts anticipate the results of the OSMO trial will have on prescribing?
• What are KOLs opinions on the design of the OSMO study?
• How do KOLs anticipate developers of other anti-IL-5s will interpret the results of the OSMO study?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved